WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Asset sale

Labcorp pays $722M upfront for BioReference testing assets

MedDevice Startups Staff · 6 days ago · 2 min read · Via MedTech Dive

Labcorp agreed to buy a group of laboratory testing businesses from BioReference Health for $722 million upfront, with up to $150 million more tied to revenue from the 4Kscore prostate test. The deal was announced October 15. BioReference is a subsidiary of Opko Health.

The assets cover clinical and women's health testing, urology, diagnostic services for correctional institutions, more than 80 patient service centers and the FDA-approved 4Kscore blood test. Labcorp expects roughly $250 million of revenue in the first year after closing, and the final price adjusts on closing revenues. The deal needs regulatory clearance, and the two businesses run separately until it closes.

The earnout is the line to read twice. Labcorp hung $150 million of the price on one assay's revenue, which is how a buyer pays for a single reimbursed test it has not yet pushed through its own ordering network.

Questions & Answers

How much is Labcorp paying for the BioReference Health assets?

Labcorp agreed on October 15, 2026 to pay $722 million upfront plus up to $150 million tied to 4Kscore revenue, for a total of up to $872 million. The final price adjusts based on closing revenues.

What is included in the Labcorp purchase of BioReference assets?

The deal covers BioReference Health's clinical and women's health testing, urology, correctional-institution diagnostics, more than 80 patient service centers and the FDA-approved 4Kscore prostate cancer blood test.

Who owns BioReference Health?

BioReference Health is a subsidiary of Opko Health. Labcorp is buying selected testing businesses from it rather than the whole company, in a deal announced October 15, 2026.

← Back to M&A